Genmab A/S acquires ProfoundBio in a landmark $1.8 billion deal
Genmab A/S (Nasdaq: GMAB) has announced the acquisition of ProfoundBio, Inc., a clinical-stage company specializing in advanced antibody-drug conjugates (ADCs) for cancer treatment. The all-cash...